Ecomax, Inc. Share Price

Equities

EMAX

US27889C3007

Other Specialty Retailers

Market Closed - OTC Markets 01:33:31 02/03/2024 am IST 5-day change 1st Jan Change
0.176 USD -9.04% Intraday chart for Ecomax, Inc. -.--% -49.71%
Sales 2022 - Sales 2023 0.42 35.45 Capitalization 23.81L 20Cr
Net income 2022 - 0 Net income 2023 - 0 EV / Sales 2022 -
Net Debt 2022 2L 1.6Cr Net Debt 2023 4L 3.47Cr EV / Sales 2023 65,89,581 x
P/E ratio 2022
-14.8 x
P/E ratio 2023
-25 x
Employees 1
Yield 2022 *
-
Yield 2023
-
Free-Float 8.59%
More Fundamentals * Assessed data
Dynamic Chart
1 day-9.04%
6 months-70.67%
Current year-49.71%
More quotes
Current year
0.18
Extreme 0.176
0.19
1 year
0.18
Extreme 0.176
1.00
3 years
0.18
Extreme 0.176
1.95
5 years
0.18
Extreme 0.176
5.70
10 years
0.02
Extreme 0.023
5.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 41 30/22/30
Members of the board TitleAgeSince
Chief Executive Officer 41 30/22/30
More insiders
Ecomax, Inc. is engaged in selling and distributing Rocitin NMN products to customers in the Territory. Rocitin NMN is a nutritional supplement manufactured by Pharmazeutische Fabrik Evers GmbH & Co. KG, a German company. Each bottle contains 60 capsules, 10080 mg of NMN. NMN, as β-Nicotinamide Mononucleotide exists in some fruits, vegetables, and poultry. It is a molecule naturally occurring in all life forms and can be transformed into a significant coenzyme NAD+ within cells, which is important to human metabolism. Its research, including Nicotinamide mononucleotide (NMN) as an anti-aging health product has shown that NAD+ levels in the body will decrease with age, and that exogenous supplementation of NMN enhances NAD+ levels and thus the function of human cells. In addition, NMN also helps to repair broken DNA, regulate the stability of DNA and cell death, and improve neurodegenerative and metabolic conditions.
More about the company